Our FGF2-STAB® has been given an interesting redo by a team of scientists from the University of Wroclaw. They have used our thermostable molecule to create cyclic and dimeric protein variants that might have higher potential in regenerative and cancer medicine. The resulting variants present different effects on the signaling cascade and modulate the pleiotropic effect of FGF2. Proposed applications of these new variants include wound healing – as cyclic FGF2-STAB® is more active and stable, anticancer therapy – as FGF2-STAB®-based drug carrier and also in glucose uptake – for diabetic patients that cannot be treated with insulin.
Have we aroused your interest? Read on…